Tekmira hammers out a way to get its Ebola drug to patients

Ebolavirus under an electron microscope--Courtesy of CDC

Tekmira ($TKMR), developer of an RNAi treatment for Ebola, has come to terms with regulators on an access program for its in-development drug, allowing the company to provide doses to patients who have contracted the deadly virus. Through agreements with the FDA and Health Canada, Tekmira said it has established a framework for supplying and administering its lead drug, TKM-Ebola. As CEO Mark Murray points out, the expanded access program for TKM-Ebola doesn't constitute a controlled clinical trial, but the infused treatment has been well-tolerated so far. Tekmira is studying the drug under a partial FDA clinical hold after the agency took issue with some safety signals. More

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.